Video

Pathophysiology of AD Treatments

Author(s):

Andrew Blauvelt, MD

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Related Content
Study Highlights Necessity of Image Quality for Deep Learning Model Diagnostic Success
December 20th 2024

Study Highlights Necessity of Image Quality for Deep Learning Model Diagnostic Success

Tim Smith
The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD
November 18th 2024

The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD

Mona Shahriari, MD, FAAD Linda Stein Gold, MD Susan Taylor, MD
Site Logo
December 19th 2024

Why Some Dermatologists Are Adopting JAKs for Uncontrolled Moderate-to-Severe Atopic Dermatitis

Default thumbnail for The Medical Sisterhood with Mona Shahriari, MD
October 18th 2024

The Medical Sisterhood: Motherhood in Medicine, with Alexandra Golant, MD

Mona Shahriari, MD, FAAD
Jessica Wong, PhD | Credit: Jessica Wong on LinkedIn
December 18th 2024

Pediatric Food Allergies Linked to Uncontrolled Atopic Dermatitis, Long-Term Prognosis

Abigail Brooks, MA
Christopher G. Youn, MD Candidate I Credit: Stanford Biosciences
December 18th 2024

Parents of Children with Atopic Dermatitis Often Sleep Less Than 7 Hours

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.